Thyquidity Solution
NDC Package 82685-360-01
Package Information
Thyquidity (levothyroxine sodium) solution is hypothyroidismTHYQUIDITY is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) SuppressionTHYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.Limitations of Use:THYQUIDITY is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with THYQUIDITY may induce hyperthyroidism [seeWarnings and Precautions (5.4)].THYQUIDITY is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. This formulation utilizes a solution delivery system. Marketed by Oliva Therapeutics, Llc, this product is identified by NDC 82685-360 and is authorized under FDA application NDA214047.
Identification & Billing
- RxCUI: 2473276 - levothyroxine sodium 100 MCG in 5 mL Oral Solution
- RxCUI: 2473276 - levothyroxine sodium 0.02 MG/ML Oral Solution
- RxCUI: 2473276 - levothyroxine sodium 100 MCG per 5 ML Oral Solution
- RxCUI: 2473276 - levothyroxine sodium 20 MCG per ML Oral Solution
- RxCUI: 2473282 - Thyquidity 100 MCG in 5 mL Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 82685 - Oliva Therapeutics, Llc
- 82685-360 - Thyquidity
- 82685-360-01 - 1 BOTTLE, GLASS in 1 CARTON / 100 mL in 1 BOTTLE, GLASS
- 82685-360 - Thyquidity
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (82685-360). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 82685-360-01 identifies a specific commercial package of 1 bottle, glass in 1 carton / 100 ml in 1 bottle, glass of Thyquidity, a human prescription drug labeled by Oliva Therapeutics, Llc. This solution is formulated for oral use and contains levothyroxine sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Oliva Therapeutics, Llc on July 01, 2025. The current certification is valid through December 31, 2027.
How is this Oliva Therapeutics, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 82685036001. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.